How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.
Kirsten M WilliamsPublished in: Blood (2016)
In past years, a diagnosis of bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplant (HCT) conferred nearly universal mortality secondary to lack of consensus for diagnostic criteria, poorly understood disease pathogenesis, and very few studies of therapeutic or supportive care interventions. Recently, however, progress has been made in these areas: revised consensus diagnostic guidelines are now available, supportive care has improved, there is greater understanding of potential mechanisms of disease, and prospective trials are being conducted. This article describes these advances and provides suggestions to optimize therapy for patients with BOS after HCT.
Keyphrases
- healthcare
- palliative care
- bone marrow
- clinical practice
- quality improvement
- stem cell transplantation
- case report
- physical activity
- acute myeloid leukemia
- pain management
- single cell
- low dose
- stem cells
- cell cycle arrest
- mesenchymal stem cells
- risk assessment
- climate change
- high dose
- cell proliferation
- cell death
- hematopoietic stem cell